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Background: Large numbers of patients with psychosis have regular meetings with key clinicians in the
community. There is little evidence on how these meetings should be conducted to be therapeutically effective.
DIALOG, a computer mediated procedure, was shown to improve outcomes in a European multi-centre trial.
DIALOG structures the patient-clinician communication and makes it patient-centred, but does not guide clinicians
as to how to respond to patients’ concerns. DIALOG has been further developed into DIALOG+, which uses
advanced software and, additionally, provides a four step approach - based on a solution focused model - for
addressing patients’ concerns. We designed a cluster randomised controlled trial to test the effectiveness of
DIALOG+ in improving treatment outcomes of patients with psychosis in the community.
Methods/design: Key workers are recruited from community mental health teams in East London and randomly
allocated to either the intervention or control group. Out of their case loads, we identify patients with
schizophrenia (F 20–29) and a moderate or lower level of subjective quality of life (MANSA score <5), who are
treated according to the allocation of their key workers. Key workers in the intervention group are trained in using
DIALOG+ and use it with each patient over a six-month period. Control patients rate their satisfaction with life and
treatment on a tablet to control for the effect of regular ratings and the use of modern technology. We are
recruiting up to 42 key workers to reach a total sample size of 180 patients. Clinical and social outcomes including
costs are assessed after 3, 6 and 12 months. Primary outcome is subjective quality-of-life at 6 months.
Discussion: The trial aims to evaluate the effectiveness of a novel intervention (DIALOG+) which uses modern
technology to support routine patient-clinician meetings in community care, makes the communication patient
centred and guides patients and clinicians to address concerns. DIALOG+ is a generic and widely applicable
intervention. If shown as effective, it can be used to improve outcomes of community care on a large scale,
ensuring that routine encounters are therapeutically effective. DIALOG+ can also be implemented across services
at relatively low additional costs.
Trial registration: Current Controlled Trials ISRCTN34757603* Correspondence: s.priebe@qmul.ac.uk
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Approximately 1% of the population are affected by
schizophrenia and related disorders with particularly
high rates in urban areas [1]. Such disorders result in
significant distress for patients and carers and account
for a substantial societal burden. They also generate
high costs to health care systems through the need for
on-going intensive care and frequent hospitalisation,
and to society at large caused by loss of employment
of patients and frequently also carers [2,3].
Patients with severe forms of schizophrenia are now
regularly cared for in the community. As a result of
major reforms of mental health care since the 1970s
and substantial additional investments in the last 10
years, multi-disciplinary community mental health care
teams have been set up in various countries including
the United Kingdom (UK) and provide on-going care.
Every patient has a key worker (usually a nurse or so-
cial worker by background) who has regular meetings
with the patient to assess their needs, engage them in
treatment, and discuss different treatment options and
co-ordinate care. Yet, the interaction in these meetings
is based more on common sense than on evidence
based methods.
Whilst research evidence suggests that a more positive
patient-clinician relationship is associated with more
favourable outcomes [4-7], there is no evidence based
intervention to achieve a better therapeutic relationship
in community mental health care. Also, until recently
there was no evidence based method to structure the
communication between patient and clinician in a way
that would eventually lead to more favourable clinical
outcomes [8].
DIALOG is the first method to structure the patient-
clinician interaction in community mental health care that
has been shown to be associated with more favourable
long term outcomes in a randomised controlled trial [9].
In this computer-mediated intervention, patients are
presented with fixed questions regarding their satisfaction
with life and treatment and their needs for additional help.
Subsequently, the ratings are displayed graphically and
can be compared with ratings from previous meetings. In
a cluster randomised controlled trial in six European
countries, the DIALOG intervention was shown to be
effective over a one year period. The intervention was
associated with better subjective quality of life (SQOL),
fewer unmet treatment needs and higher treatment sat-
isfaction in patients with psychosis. The overall effect
size was small. A stronger effect (medium effect size)
was observed in the study site in the United Kingdom
(East London) and in patients with more problematic
baseline scores [10].
Following the trial, the National Institute for Health
Research in the UK funded a programme to develop theintervention further both in terms of improving the
technology and linking it with a simple psychological
intervention informed by principles of Solution Focussed
Therapy (SFT) and Cognitive Behavioural Therapy (CBT).
The new intervention, combining the original intervention
with a new 4-step approach to address problems raised by
the patient, is called DIALOG+. The 4-step approach has
been developed based on experiences with DIALOG in
practice and involving experts in SFT and CBT. The four
steps consist of exploring the reasons for the dissatisfac-
tion or wish for additional help and identifying positive
coping skills; a forward looking consideration of best
hopes and/or small changes; a discussion of all options
for helpful actions by the patient, the clinician or other
people; and an agreement of actions to be taken. DIA-
LOG+ is manualised, and a training programme has
been designed with follow-up supervision for clinicians.
DIALOG+ differs considerably from the initial DIA-
LOG intervention. DIALOG+ involves a new version of
the software (DIALOG 2.0) on a new platform (a tablet),
further structures clinicians’ behaviour according to the
DIALOG+ manual, and involves training of clinicians.
DIALOG+ aims to provide a way to deal with the spe-
cific concerns raised by the patient and, hence, equip the
clinician as well as the patient with a method to explore
and deal with problems.
Furthermore, the DIALOG+ intervention is more inten-
sive. It is being delivered at least once a month over a six
month period, rather than every two months over a one-
year period, as in the original trial. We have included a
wider range of patients, as opposed to those with persist-
ent disorders who had been in care for an average of 15
years in the previous study. Finally, we are comparing the
intervention with a more defined control condition than
treatment as usual. This will help to control for the effect
of the implementation of an electronic device in the clin-
ical setting and the assessment of satisfaction; without
providing feedback, expanding on problematic domains or
exploring needs for additional help. All of these differences
justify a new trial testing the effectiveness of DIALOG+.
Against this background, the trial aims to test whether
the regular use of the DIALOG+ intervention over a six
month period improves patients’ outcomes, and if it is
cost-effective.
Methods
Study design
In a pragmatic cluster randomised controlled trial key
workers and their patients are randomly allocated to the
experimental condition using DIALOG+ or the control
condition with regular ratings of satisfaction using the
DIALOG Scale on a tablet. Both conditions are in addition
to treatment as usual. There are four data collection
points: baseline, and 3, 6 and 12 month follow-ups.
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Health Teams in East London (East London NHS Foun-
dation Trust). We aim to recruit a maximum of seven
patients per key worker. If necessary, the patients to
approach for participation are randomly selected from
the pool of eligible patients on a key worker’s caseload.
However, this is rare, and usually we recruit fewer than
seven patients per key worker. Once all consenting pa-
tients (per key worker) meeting the inclusion criteria have
been recruited, the key worker – and their patients – are
randomly allocated to either the intervention or control
condition. Clustering of clinicians prevents contamination
effects in the study. Randomisation is carried out via
e-mail by an independent statistician at the Pragmatic
Clinical Trials Unit of Queen Mary, University of London.
The unit of randomisation is the key worker using ran-
domly permuted blocks with variable block sizes and equal
allocation ratio.
Key workers use the intervention with their patients
for a period of six months. Midway through receiving
the intervention (3 months), at the end of the interven-
tion period (6 months), and after a 6 month follow-up
period patients are interviewed by researchers and out-
comes assessed. These assessments are conducted on
NHS sites or in the community.
Researchers assessing the outcomes are blinded to
the allocation of the patients. If blinding cannot be
maintained, we put researchers working at the Unit for
Social and Community Psychiatry at Queen Mary, Uni-
versity of London (who are independent of the core re-
search team) into contact with patients via telephone
for conducting the assessment of the primary outcome
and, as far as feasible, secondary outcomes. In such
cases, patients are asked not to discuss the treatment
they received for the duration of the call.
Planned interventions
Key workers and their patients in the experimental con-
dition are instructed to use DIALOG+ at least once per
month over a six month period, although this may vary
due to the practical organisation of care. DIALOG+ is
used as defined in the accompanying manual, and the
DIALOG 2.0 software runs on a tablet. All key workers
in the experimental group are trained in one session be-
fore beginning the intervention. The training is provided
by two experienced clinicians who are independent of
the research study team (both qualified in psychological
treatments), with the number of training sessions di-
vided between the two. For practical reasons, the major-
ity of training is carried out one to one. During the
training session, key workers are provided with reading
material and the DIALOG+ manual, have the procedure
demonstrated to them, participate in a role-play exercise,
and have the opportunity to watch videos. For each keyworker, the first DIALOG+ session with a patient is
audio-recorded and feedback is provided by their trainer
via a follow-up session. A subsequent DIALOG+ session
is also audio-recorded to provide further feedback.
Throughout the duration of the study key workers can
contact the trainers for further sessions for support and
advice at any time.
Key workers and patients in the experimental group
may decide to continue with DIALOG+ after the end of
the six month intervention. This will be documented
and considered in the analysis of outcomes after the
follow-up period.
The control condition includes treatment as usual plus
a defined intervention that also involves the use of a tab-
let and an assessment of the patient’s satisfaction. The
patients use the device to rate their satisfaction on the
11 domains of the DIALOG scale. The intervention is
delivered with the same frequency as DIALOG+, with
such assessments being undertaken after a routine meet-
ing. The key workers are instructed to demonstrate the
software to the patients prior to their first time complet-
ing the scale. Patients need to complete the scale alone
without the key worker’s help, and patients and key
workers are not to discuss the ratings. This is intended
to control for the effect of the implementation of an
electronic device in the clinical setting and the regular
assessment of satisfaction.Inclusion and exclusion criteria
To reflect the pragmatic nature of the trial, there are
wide inclusion criteria and very few exclusion criteria for
both clinicians and patients. The inclusion criteria for
patients are wider than in the original DIALOG trial to
test whether patients with more acute disorders, who
have not been in care for many years and whose treat-
ment in secondary services may not continue for an-
other year, can also be recruited and benefit from the
intervention.Key workers
Clinicians are key workers currently employed in the
East London NHS Foundation Trust, working in com-
munity mental health teams and meeting the following
criteria:
 Professional qualification as a clinician (nurse, social
worker, psychologist, occupational therapist, doctor);
 More than 6 months experience of working in
community mental health care;
 Working as care coordinator.
Clinicians are excluded if they have to attend a sched-
uled training course of more than two weeks’ time during
Priebe et al. BMC Psychiatry 2013, 13:173 Page 4 of 7
http://www.biomedcentral.com/1471-244X/13/173the study period and will not continue their care-
coordinating role whilst attending training.
Patients
We recruit patients in the East London NHS Foundation
Trust, currently treated in a community mental health
care team, fulfilling the following criteria:
 Treatment in a community mental health care team
for at least one month;
 No planned discharge for the next six months;
 Clinical diagnosis of schizophrenia or a related
disorder (F20-29);
 Age between 18 and 65 years;
 A mean score of lower than 5 on the MANSA;
 Capacity to give informed consent.
Exclusion criteria
 Insufficient command of the English language for
conducting meetings in English and filling in the
assessment instruments of outcomes;
 A mean score of 5 or more on the MANSA;
 Learning difficulties.
Outcome measures
Outcomes are assessed at baseline and after 3, 6, and 12
months.
The primary outcome is subjective quality of life,
measured on the Manchester Short Assessment of
Quality of Life (MANSA) (as in the original trial test-
ing DIALOG) [11]
Secondary outcomes for the trial are:
 Recovery as measured on the severity parts of each
of the 24 items of the CHOICE scale [12]
(satisfaction, i.e. the second part of each item, is
already assessed on the MANSA)
 Objective Social Outcomes (SIX) [13], also assessed
using the MANSA (sections 2 and 3), at 6 and 12
months only
 Social contacts in the last week in a structured
interview
 Treatment Satisfaction on the Client Satisfaction
Questionnaire (CSQ-8) [14]
 The Therapeutic Relationship on the Scale for
Assessing Therapeutic Relationships in community
mental health care (patient and clinician
versions) [15]
 Needs on the Camberwell Assessment of Need
Short Appraisal Schedule, patient-rated version [16]
 Self-Efficacy on the General Self-Efficacy Scale [17]
 Psychopathological Symptoms on the Brief
Psychiatric Rating Scale [18] Costs of care, assessed on the Client Service Receipt
Inventory [19], i.e. data on the use and frequency of
inpatient care, outpatient care (face to face
meetings), and other health services which are
obtained from case notes, electronic databases and
patients themselves.
 Mental well-being on the Warwick-Edinburgh
Mental Well-Being Scale (WEMWBS) [20].
All outcomes are assessed at baseline and after 3, 6,
and 12 months.
Qualitative assessments
For assessing the feasibility of the intervention, adherence
to the manual and its effects in the patient-clinician meet-
ings, each patient-clinician pair in the intervention group
has one of their meetings video-taped (or when unpracti-
cal audio-taped) and analysed. In the control group, we do
the same for 20% of the sample. Adherence to manual in
the intervention group is assessed against the manual for
DIALOG+, using an adherence scale developed by the re-
search team.
The software records automatically what domains
were explicitly discussed in DIALOG+ and what actions
were agreed. This information is synchronised to a ser-
ver that un-blinded members of the research team have
access to.
At the end of the intervention, separate focus groups
will be conducted and audio-taped with patients and cli-
nicians in the intervention group to obtain their experi-
ences and suggestions for improvements.
Statistical analysis
The primary analysis of subjective quality of life as mea-
sured on the MANSA will be conducted using a general-
ised linear model with a fixed effect for treatment and
baseline MANSA score and a random effect for key
worker to account for clustering.
Secondary outcomes will be analysed using a similar
approach, with adjustment for corresponding baseline
values.
Sensitivity analyses will be performed to explore the
impact of missing data on our conclusions.
All analysis will be conducted under the intention to
treat principle and significance testing will be at the 5%
level (2-sided). A full analysis plan will be developed and
agreed prior to any analysis or unblinding of the data.
Results will be presented to follow the recommendations
given in the CONSORT statement extension for the
reporting of cluster randomised trials.
Economic evaluation
The cost of the DIALOG and DIALOG+ interventions
are expected to be low and will mainly comprise any
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vention. There will though be costs associated with (i)
refining the procedure and developing DIALOG+ (but
when apportioned across all patients who might receive
the intervention these will be minimal), and (ii) training
key workers in their use. A nominal developmental cost
per patient will be included and resources and time re-
quired for training will be measured and costed. Total
costs will be calculated by combining the intervention
costs with those associated with the use of other ser-
vices. Cost differences will be analysed using bootstrap
methods due to the expected skewness in the data distri-
butions. Costs will be combined with the primary out-
come measure in the form of a cost-effectiveness analysis.
If costs are lower for one group than another and
outomes are better then it will be ‘dominant’ in terms
of cost-effectiveness. If costs are higher and outcomes
are better then an incremental cost-effectiveness ratio
will indicate the extra costs incurred to produce an
extra unit-improvement in quality of life. Uncertainty
around these estimates will be analysed using cost-
effectiveness planes and cost-effectiveness acceptability
curves [21].
Qualitative analysis
Videotapes will be analysed according to specific criteria
(using a purposely developed adherence scale) for adher-
ence to the manual. Audiotapes from focus groups will
be analysed using thematic analysis.
Proposed sample size
We aim to recruit 42 key workers in total; with each key
worker providing an average of four to five patients, pro-
viding a total of 180 patients.
Assuming a practically negligible cluster effect (as in
the original trial) the sample size will be sufficient to
detect a medium effect size of 0.5 (Cohen’s D) with 80%
power at the 5% significance level (2-sided). A slightly
higher effect of 0.57 will be detected with 90% power.
The effect size of 0.5 would require that at the end of
the intervention patients in the experimental condition
rate their satisfaction with at least 3 out of 12 life do-
mains in the MANSA at least one point higher than pa-
tients in the control condition.
This sample size allows for a cluster attrition rate of 6
key workers (30 patients) and a patient dropout rate of
less than 10%.
Recruiting participants and obtaining informed consent
Clinicians working in Community Mental Health Teams
in the East London boroughs of Hackney, Newham and
Tower Hamlets are approached by the managers of East
London NHS Foundation Trust and asked to participatein the study. Written informed consent to participate is
obtained from individual key workers.
Key workers, supported by research and administrative
staff, identify patients on their caseloads fulfilling the in-
clusion criteria, and then ask suitable patients for con-
sent to be approached by a researcher. If the answer is
yes, a researcher arranges a meeting with the patient to
provide an information sheet and to discuss the project
in full. At the meeting, the researcher goes through the
information sheet, explains the study, obtains written in-
formed consent, and establishes all inclusion criteria.
Patients are informed through their consent forms that
they are free to withdraw from the study at any time,
without giving reason and without any negative conse-
quences. This will be emphasised by the researcher in all
discussions explaining the study and prior to taking in-
formed consent.
As part of this process we obtain consent for one of
the patient’s sessions with their key worker to be video
recorded in order to assess adherence to the procedure,
and for patients to attend an audio-recorded focus group
at the end of their intervention period to discuss their
experiences with other patients. This is optional for pa-
tients, and if they do not wish to be video recorded or
take part in the focus group this will not impact on their
participation in the study.
Ethics approval
The study has been approved by the London-Stanmore
National Research Ethics Service Committee (REC refer-
ence 12/LO/1145). All data will be stored in line with
the Data Protection Act. All audio and video recorded
data will be encrypted and password protected.
Trial steering committee and data monitoring and ethics
committee
Both a Trial Steering Committee and a Data Monitoring
and Ethics Committee have been set up. No formal in-
terim efficacy analyses have been planned.
Discussion
At present, large numbers of patients with psychosis
regularly meet key workers in community mental health
teams, but the patient-clinician interactions are not
guided by evidenced based principles. A method to make
these interactions more effective will not be a specialist
programme for a small number of patients, but a generic
method that can be utilised in routine care throughout
the NHS and potentially in other countries with similar
services providing care in the community for patient
with psychosis (DIALOG+). It does not require setting
up new services or restructuring of organisations. It can
be implemented at relatively low costs, particularly as it
will not require extensive training of clinical staff, and
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the same time. Thus, even small health and social gains
for individual patients will add up to substantial public
health effects. This also applies to potential cost savings.
The FOCUS study (in which patients’ outcomes were
assessed by researchers and fed back to clinicians without
structuring clinician-patient communication) suggested
annual cost savings of regular outcome data feedback
(which is also provided in DIALOG+) equivalent to £5172
per patient through reduced bed use [22]. If replicated for
only 20% of patients with schizophrenia and related disor-
ders in community care in the NHS, the savings would ex-
ceed £100 million every year.
The procedure of DIALOG+ will also provide regular
outcome data, i.e. patients’ ratings of satisfaction with life,
treatment satisfaction and needs for further care. This data
can be used to evaluate services on a local, regional and
national level. So far, attempts to establish outcome assess-
ment in routine community mental health care have
largely failed, partly because it is difficult to motivate clini-
cians and patients to rate and enter outcome data on a
regular basis. DIALOG+ provides a method to generate
such data in way that is meaningful to clinicians and pa-
tients, and is likely to facilitate routine outcome assess-
ment in secondary mental health services in the NHS.
The trial pursues the ambitious aim of testing a new
intervention that can be rolled out widely and at low
costs, and – if successful - ensures that routine patient-
clinician meetings in the community are therapeutically
effective. The intervention is based on well-established
models of psychological treatments, in particular on so-
lution focused therapy, but has been specified so that it
is easy to train, enables clinicians to bring in existing
therapeutic skills and uses modern technologies. The trial
involves various teams across East London and is prag-
matic in terms of being implemented in routine care.
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